MIVI Neuroscience (MIVI) is a health care startup founded in 2013, based in the United States. Their slogan, "The Next Generation of Neurointervention," encapsulates their mission to revolutionize interventional treatment for acute ischemic stroke (AIS) patients. MIVI aims to achieve life-giving results through their proprietary technology, meticulously developed in collaboration with physicians to enhance the safety and efficacy of AIS therapy.
In their latest funding round on 21 January 2021, MIVI secured a substantial $35.00M Series B investment from notable investors including Aphelion Capital, Concord Health Partners, Deerfield Management, and Perceptive Advisors. This financial backing not only underscores MIVI's growth potential but also signifies the confidence top industry players have in their innovative approach to addressing critical medical needs. As they continue to advance their groundbreaking technologies, MIVI Neuroscience is poised to make a significant impact in the field of neurointervention and transform the landscape of stroke treatment.
